Practical Considerations and Implementation of Automated Insulin Delivery Systems.

IF 6.3 2区 医学 Q1 ENDOCRINOLOGY & METABOLISM
Laurel H Messer, Gregory P Forlenza, Linda Gonder-Frederick, Korey Hood, Osagie Ebekozien, Katharine Barnard-Kelly, Lori M Laffel, Jennifer L Sherr, Rayhan Lal, Stuart A Weinzimer
{"title":"Practical Considerations and Implementation of Automated Insulin Delivery Systems.","authors":"Laurel H Messer, Gregory P Forlenza, Linda Gonder-Frederick, Korey Hood, Osagie Ebekozien, Katharine Barnard-Kelly, Lori M Laffel, Jennifer L Sherr, Rayhan Lal, Stuart A Weinzimer","doi":"10.1089/dia.2025.0132","DOIUrl":null,"url":null,"abstract":"<p><p>Automated Insulin Delivery (AID) is in a new era of implementation challenges and opportunities for people with diabetes (PWD) and healthcare providers (HCPs). Beyond technologic variation, cost, access, and HCP endorsement/experience lead to uneven uptake of AID technologies, and attenuate universal ease of use. For AID to be broadly implemented, we must prioritize the lived experience for PWD, and consider how to alleviate burden to promote holistic wellbeing. Expectations and education help HCPs and PWD navigate the similarities and differences between AID devices, and help find common ties: users need to give the system time to work, learn to trust it, and not try to \"trick\" the system. Despite these learnings, disparities in uptake exist, both in clinical trials and in routine clinical care. Strategies to proactively address AID disparities are needed at multiple levels, all of which increase in importance as AID becomes more common for people with type 2 diabetes. Further, broader implementation will require comprehensive healthcare system integration efforts, including new data solutions. Overall, the success of AID requires ongoing transformation of clinical paradigms, with lockstep alignment between PWD and their families, healthcare professionals, researchers, funders, policy makers, and industry partners.</p>","PeriodicalId":11159,"journal":{"name":"Diabetes technology & therapeutics","volume":"27 S3","pages":"S72-S78"},"PeriodicalIF":6.3000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes technology & therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/dia.2025.0132","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Automated Insulin Delivery (AID) is in a new era of implementation challenges and opportunities for people with diabetes (PWD) and healthcare providers (HCPs). Beyond technologic variation, cost, access, and HCP endorsement/experience lead to uneven uptake of AID technologies, and attenuate universal ease of use. For AID to be broadly implemented, we must prioritize the lived experience for PWD, and consider how to alleviate burden to promote holistic wellbeing. Expectations and education help HCPs and PWD navigate the similarities and differences between AID devices, and help find common ties: users need to give the system time to work, learn to trust it, and not try to "trick" the system. Despite these learnings, disparities in uptake exist, both in clinical trials and in routine clinical care. Strategies to proactively address AID disparities are needed at multiple levels, all of which increase in importance as AID becomes more common for people with type 2 diabetes. Further, broader implementation will require comprehensive healthcare system integration efforts, including new data solutions. Overall, the success of AID requires ongoing transformation of clinical paradigms, with lockstep alignment between PWD and their families, healthcare professionals, researchers, funders, policy makers, and industry partners.

自动化胰岛素输送系统的实际考虑和实施。
对于糖尿病患者(PWD)和医疗保健提供者(HCPs)来说,自动化胰岛素输送(AID)正处于一个实施挑战和机遇并存的新时代。除了技术差异之外,成本、可及性和卫生控制方案认可/经验导致艾滋病技术接受程度不均衡,并削弱了普遍使用的便利性。要广泛推行援助,我们必须优先考虑残疾人士的生活体验,并考虑如何减轻负担,以促进整体福祉。期望和教育可以帮助hcp和PWD了解AID设备之间的异同,并帮助找到共同点:用户需要给系统时间来工作,学会信任它,而不是试图“欺骗”系统。尽管有这些研究成果,但在临床试验和常规临床护理中,摄取的差异仍然存在。需要在多个层面积极解决艾滋病差距的战略,随着艾滋病在2型糖尿病患者中越来越普遍,所有这些战略都变得越来越重要。此外,更广泛的实施将需要全面的医疗保健系统集成工作,包括新的数据解决方案。总的来说,艾滋病的成功需要临床范例的持续转变,需要残疾人及其家庭、医疗保健专业人员、研究人员、资助者、决策者和行业合作伙伴之间的步调一致。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Diabetes technology & therapeutics
Diabetes technology & therapeutics 医学-内分泌学与代谢
CiteScore
10.60
自引率
14.80%
发文量
145
审稿时长
3-8 weeks
期刊介绍: Diabetes Technology & Therapeutics is the only peer-reviewed journal providing healthcare professionals with information on new devices, drugs, drug delivery systems, and software for managing patients with diabetes. This leading international journal delivers practical information and comprehensive coverage of cutting-edge technologies and therapeutics in the field, and each issue highlights new pharmacological and device developments to optimize patient care.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信